PDCD1 and cancer: Immunotherapy in the form of immune checkpoint inhibitors (ICIs), such as monoclonal antibodies (mAbs) targeting PD-1 and PD-L1, have revolutionized the treatment for various cancer types [6,7,8,9,10].